More than 100 House and Sen­ate Re­pub­li­cans call on new FDA com­mish to re­verse or­der on mail-or­der abor­tion pills

4 years ago
FDA+

Covid-19 roundup: Val­ne­va runs in­to EMA ques­tions, still ex­pects March au­tho­riza­tion; Cana­da ap­proves first ...

4 years ago
Coronavirus

Russ­ian in­va­sion of Ukraine threat­ens hun­dreds of clin­i­cal tri­als

4 years ago
R&D

In two sep­a­rate moves, Bio­haven seeks to re­pur­pose failed Bris­tol My­ers/Roche Duchenne drug while buy­ing out small ...

4 years ago
Deals

Japan, UK pledge new funds to CEPI's $3.5B pan­dem­ic pre­pared­ness plan, with eye to­ward fu­ture out­breaks

4 years ago
Coronavirus

Watch out, No­var­tis: Eli Lil­ly, Boehringer In­gel­heim notch broad heart fail­ure OK for Jar­diance

4 years ago
Pharma
FDA+

As­traZeneca's Evusheld and GSK's sotro­vimab lose ef­fi­ca­cy against Omi­cron's sub­vari­ants

4 years ago
FDA+
Coronavirus

Or­p­hazyme runs in­to an­oth­er set­back as Eu­rope ap­pears un­like­ly to ap­prove its FDA-re­ject­ed drug

4 years ago
FDA+

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ...

4 years ago
Peer Review

For biotech, Russ­ian in­va­sion of Ukraine threat­ens to up­end a slew of ear­ly-stage R&D projects

4 years ago
R&D

Sanofi sig­nals a big in­ter­est in on­col­o­gy as it adds a can­cer R&D star to the board

4 years ago
Pharma

Last year was one of the 'most event­ful in US biosim­i­lars his­to­ry,' but these an­a­lysts say 2022 should be 'a turn­ing ...

4 years ago
Pharma

Ab­b­Vie slams the pen­sion door to new hires as Big Phar­ma hold­outs fi­nal­ly join the mi­gra­tion to 401Ks

4 years ago
Pharma

Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

4 years ago
Pharma
Marketing

Pub­lic Cit­i­zen picks apart Cures 2.0 draft leg­is­la­tion, crit­i­ciz­ing sev­er­al RWE pro­vi­sions

4 years ago
FDA+

On a roll, Re­ci­pharm wraps up its sec­ond and third CD­MO ac­qui­si­tions this month

4 years ago
Pharma
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Scot­tish gov­ern­ment in­vests $27M in Val­neva's Covid-19 man­u­fac­tur­ing; Mod­er­na ...

4 years ago
Manufacturing

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

4 years ago
R&D

Am­i­cus and Per­cep­tive call off SPAC merg­er for gene ther­a­py spin­out af­ter re­cent set­back

4 years ago
Deals

Mer­ck drops out of a $125M KRAS al­liance with Mod­er­na, tak­ing a step away from the Covid-19 star

4 years ago
Deals
Cell/Gene Tx

When a cit­i­zen pe­ti­tion works: FDA's re­view of Unit­ed Ther­a­peu­tic­s' PAH drug ex­tend­ed to May

4 years ago
FDA+

Pre­ci­sion im­munol­o­gy play­er bags $110M to fund its work on 'dis­ease sig­na­ture' tests

4 years ago
Financing
Diagnostics

Pfiz­er drops case against ex-staffer ac­cused of steal­ing trade se­crets — in­clud­ing de­tails about Covid-19 vac­cine

4 years ago
People
Pharma

Cana­da wants to clear the way for more de­cen­tral­ized clin­i­cal tri­als: Will the US fol­low suit?

4 years ago
FDA+
First page Previous page 568569570571572573574 Next page Last page
A service from the Financial Times